- Home
- CNP vs ROIV Comparison
CNP vs ROIV Comparison
Compare CNP & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CNP | ROIV |
|---|---|---|
| Founded | 1866 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.6B | 25.1B |
| IPO Year | 2001 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CNP | ROIV |
|---|---|---|
| Price | $39.53 | $34.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 9 |
| Target Price | ★ $44.08 | $28.94 |
| AVG Volume (30 Days) | 5.7M | ★ 7.1M |
| Earning Date | 04-23-2026 | 05-28-2026 |
| Dividend Yield | ★ 2.15% | N/A |
| EPS Growth | ★ 1.27 | N/A |
| EPS | ★ 0.48 | N/A |
| Revenue | ★ $9,357,000,000.00 | $8,260,000.00 |
| Revenue This Year | $7.02 | N/A |
| Revenue Next Year | $4.93 | $744.61 |
| P/E Ratio | $82.23 | ★ N/A |
| Revenue Growth | ★ 8.26 | N/A |
| 52 Week Low | $36.61 | $12.53 |
| 52 Week High | $45.26 | $37.97 |
Technical Indicators
Market Signals| Indicator | CNP | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 39.38 | 39.96 |
| Support Level | $38.42 | $33.01 |
| Resistance Level | $40.07 | $37.49 |
| Average True Range (ATR) | 0.74 | 1.19 |
| MACD | 0.07 | -0.38 |
| Stochastic Oscillator | 35.66 | 10.24 |
Price Performance
Historical ComparisonAbout CNP CenterPoint Energy Inc (Holding Co)
CenterPoint Energy owns a portfolio of businesses. Its regulated electric utilities provide transmission and distribution services to more than 2.5 million customers in the Houston area, southern Indiana, and west central Ohio.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.